The DOLF Team’s 2022: Year in Review

As we look towards a new year, we wanted to share some highlights from 2022, a year that saw many new advances and developments in our research on Lymphatic Filariasis (LF) and Onchocerciasis (Oncho). LF research Cote d’Ivoire. In late winter, DOLF team members traveled to Côte d’Ivoire for 12-month follow-up visits for patients enrolled […]

The DOLF Team’s Work to Improve Prospects for Elimination of LF Featured in a Special Supplement Published in the Am. J. Trop. Med. Hyg. (March 2022)

The DOLF project ( led clinical trials and community studies of the safety and efficacy of a single-dose triple-drug therapy (IDA) for Lymphatic Filariasis (LF). IDA is now being used in mass drug administration (MDA) programs in many countries to accelerate LF elimination. This work was supported by grants from the Bill & Melinda Gates […]